Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
暂无分享,去创建一个
D. Slamon | R. Seshadri | G. Pauletti | H. Rong | D. Slamon | H Peng | H. Peng | D J Slamon | R Seshadri | G Pauletti | S Dandekar | H Rong | L Ramos | Hongjun Peng | S. Dandekar | L. Ramos | H. Rong | Suganda Dandekar | Ram Seshadri | Lilllian Ramos
[1] J W Gray,et al. Molecular cytogenetics in human cancer diagnosis , 1992, Cancer.
[2] M. Fernö,et al. ERBB2 amplification in breast cancer with a high rate of proliferation. , 1991, Oncogene.
[3] K. Sugimachi,et al. Grb7 signal transduction protein mediates metastatic progression of esophageal carcinoma , 2000, Journal of cellular physiology.
[4] A. Ullrich,et al. Studies of the HER-2/neu Proto-Oncogene in Human Breast Cancer , 1989 .
[5] D. Slamon,et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.
[6] D. Horsfall,et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Maia. Immunohistochemical assays for HER2 overexpression. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S J Schnitt,et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] A. Harris,et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.
[10] T. Fleming,et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .
[11] D. Stern,et al. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. , 1996, British Journal of Cancer.
[12] K. Leslie,et al. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. , 1990, Archives of pathology & laboratory medicine.
[13] Donald E. Henson,et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases , 1989 .
[14] Persons Dl,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .
[15] J. Fletcher,et al. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. , 1999, Seminars in cancer biology.
[16] D. Horsfall,et al. Relationship between p53 gene abnormalities and other tumour characteristics in breast‐cancer prognosis , 1996, International journal of cancer.
[17] R. Fourney,et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. , 1991, Cancer research.
[18] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Slamon,et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.
[20] D. Pinkel,et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[21] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[22] J. Guan,et al. Association of Focal Adhesion Kinase with Grb7 and Its Role in Cell Migration* , 1999, The Journal of Biological Chemistry.
[23] D. Berry,et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.
[24] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[25] D. Cox. Regression Models and Life-Tables , 1972 .
[26] K. Alitalo,et al. Identification of Tek/Tie2 Binding Partners , 1999, The Journal of Biological Chemistry.
[27] J. Ingle,et al. Increased HER2 with U.S. Food and Drug Administration-approved antibody. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Birnbaum,et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation , 1994, The Journal of pathology.
[29] B Fisher,et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.
[30] R. Espinosa,et al. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[31] F. Apiou,et al. Characterization of recurrent homogeneously staining regions in 72 breast carcinomas , 1998, Genes, chromosomes & cancer.
[32] R Akita,et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.
[33] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Doherty,et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. , 1998, Cancer research.
[35] P. D’Eustachio,et al. The SH2 domain protein GRB‐7 is co‐amplified, overexpressed and in a tight complex with HER2 in breast cancer. , 1994, The EMBO journal.
[36] F. Waldman,et al. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. , 1995, Cancer research.
[37] B. Groner,et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.
[38] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[39] A. Gown,et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.